(Philadelphia,
PA) - Can H. Ficicioglu, MD, PhD, has been named
an Assistant Professor in the Department of Pediatrics,
division of Metabolism (biochemical genetics), at the
University of Pennsylvania School of Medicine.
Dr. Ficicioglu's research interests include the study
of outcomes in expanded newborn screening; enzyme replacement
treatment on lysosomal storage diseases; and bone marrow
transplantations for inborn errors in metabolism. His
research has been published in the Journal of Inherited
Metabolic Disease, Turkish Journal of Medical &
Biological Research, The Turkish Journal of Pediatrics,
Neuropediatrics, the Istanbul Cocuk Klinigi Dergisi
and Pediatric Neurology, among others.
In 1985, Dr. Ficicioglu received his MD from the University
of Istanbul, Cerrahpasa Medical School, and earned his
PhD from the University of Marmara in Turkey in 1996.
He performed residencies at New York Medical College
(St. Vincent's Medical Center), Albert Einstein Medical
College (Montefiore Medical Center), and the University
of Istanbul. He completed a clinical fellowship in the
division of Genetics and Metabolism at Harvard Medical
School, Children's Hospital of Boston.
He is a member of The Society for the Study of Inborn
Errors of Metabolism, the European Association for the
Study of Diabetes and the American Academy of Pediatrics.
He was invited to lecture at the National Metabolism
Congress in Izmir, Turkey, on the topic, 'NTBC treatment
in Tyrosinemia type 1.' In 1994, Dr. Ficicioglu authored
the book, "Diabetes Guide" and in 1993, he
co-authored the book, "Advances in Metabolic Diseases".
# # #
.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.